search button

Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review)

  • Authors:
    • Sunao Shoji
    • Xian Yang Tang
    • Haruhiro Sato
    • Yukio Usui
    • Toyoaki Uchida
    • Toshiro Terachi

  • View Affiliations

  • Published online on: September 1, 2010     https://doi.org/10.3892/ol_00000136
  • Pages: 783-788
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer metastasis is a leading cause of death in cancer patients and is a multistep process involving complex interactions between tumor and host cells. To metastasize, tumor cells must invade or migrate from the primary tumor and be transported to close or distant secondary sites. A tumor cell should successfully accomplish each step of the pathway or metastasis may not develop. KiSS-1 is a human metastasis suppressor gene that inhibits metastasis of human melanomas and breast carcinomas without affecting tumorigenicity. KiSS-1 encodes a carboxy-terminally amidated peptide with 54 amino-acid residues. The peptide was isolated from human placenta as the endogenous ligand of an orphan G-protein-coupled receptor and termed ‘metastin’. The literature reports metastin related to human carcinoma, such as melanoma, thyroid cancer, esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma, pancreatic carcinoma, as well as breast, ovarian, bladder and kidney cancer. These malignancies are difficult to treat and, even in early-stage cancer, a number of patients develop metastasis shortly after surgery. Studies have suggested that metastin inhibits tumor invasion or migration through focal adhesion kinase, paxillin, MAP kinase or Rho A. Additionally, metastin may be a biomarker in ESCC, pancreatic carcinoma and bladder cancer. Metastin has potential as a suitable biomarker in the identification of tumors with high metastatic potential and as a novel effective treatment modality for patients with metastasis.
View Figures
View References

Related Articles

Journal Cover

September-October 2010
Volume 1 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Shoji S, Tang XY, Sato H, Usui Y, Uchida T and Terachi T: Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review) . Oncol Lett 1: 783-788, 2010
APA
Shoji, S., Tang, X.Y., Sato, H., Usui, Y., Uchida, T., & Terachi, T. (2010). Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review) . Oncology Letters, 1, 783-788. https://doi.org/10.3892/ol_00000136
MLA
Shoji, S., Tang, X. Y., Sato, H., Usui, Y., Uchida, T., Terachi, T."Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review) ". Oncology Letters 1.5 (2010): 783-788.
Chicago
Shoji, S., Tang, X. Y., Sato, H., Usui, Y., Uchida, T., Terachi, T."Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review) ". Oncology Letters 1, no. 5 (2010): 783-788. https://doi.org/10.3892/ol_00000136